Freeline Therapeutics Holdings plc (FRLN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Stevenage Bioscience Catalyst
Stevenage, SG1 2FX
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 14 3890 6870
Website
Sector
Healthcare
Industry
Biotechnology
Employees
152
First IPO Date
August 07, 2020
| Name | Title | Pay | Year Born |
| Michael J. Parini | Chief Executive Officer & Executive Director | 2.16M | 1975 |
| Paul Schneider | Chief Financial Officer & Director | 0 | 1971 |
| Amy J. Spandau | Interim Head of Finance | 0 | 1975 |
| Naomi Aoki | Senior Vice President of Corporation Communications & Investor Relations | 0 | N/A |
| Nicole Jones | Chief People Officer | 0 | 1971 |
| Pamela Foulds | Chief Medical Officer | 0 | 1970 |
| Henning R. Stennicke | Chief Scientific Officer | 0 | 1968 |
| James Bircher | Chief Technical Operations Officer | 0 | 1968 |
Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.